Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a young girl with trichothiodystrophy and suggests the need for early diagnosis and multidisciplinary interventions for her educational challenges.

This study found that the majority of "hypoallergenic" hair dyes still triggered allergic reactions in patients sensitive to para-phenylenediamine.

This article reviews the centenary of the British Association of Dermatologists by highlighting significant papers from its journals, with no new clinical results reported.

This study developed a handheld card to simplify the calculation of the SALT score for assessing alopecia areata severity, noting that while it accelerates the process, formal validation against existing methods is still needed.

This review discusses the potential of Janus kinase inhibitors as a promising new treatment for alopecia areata, suggesting they could become a first-line therapy in the future, but reports no new clinical results.

This study suggests that D2O increases hair length in nude mice by extending the hair cycle duration, particularly the hair-existing phase, which is associated with increased mast cell density.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

This study reported six pediatric cases of temporal triangular alopecia and highlighted the use of trichoscopy to distinguish it by detecting a distinctive carpet of vellus hair, helping to differentiate TTA from other hair loss conditions.

This article updates a diagnostic tool (SALT II) for assessing hair loss by adding more precise measurements of scalp surface area, particularly useful for various types of alopecia.

This systematic review concluded that oral JAK inhibitors, such as baricitinib and deuruxolitinib, are effective and generally well-tolerated treatments for moderate-to-severe alopecia areata, offering advantages over traditional therapies.

In this case report, an 8-year-old with severe alopecia areata and atopic dermatitis experienced significant hair regrowth and improved dermatitis symptoms after treatment with dupilumab followed by baricitinib, with no major side effects observed.

This case report describes the successful treatment of alopecia areata using Ayurvedic management, suggesting that Ayurveda may aid in rebalancing the body and promoting hair regrowth in autoimmune conditions.

In this study, withdrawal of baricitinib therapy in patients with severe alopecia areata who had achieved hair regrowth led to a loss of benefit in almost all patients, suggesting that continued treatment is necessary to maintain hair regrowth.

This article reports a case of rapidly progressive alopecia areata totalis in a COVID-19 patient that did not respond to treatment with tofacitinib; no new clinical results are discussed.

This study reports that topical immunotherapy with SADBE and DPCP is the most effective short-term treatment for hair regrowth in children with severe alopecia areata compared to other treatments.

This article reviews the need for a reliable and safe method to prevent alopecia areata from progressing to more severe states and reports no new research findings.

This study observed that baricitinib treatment led to significant improvements in hair regrowth and quality of life scores in adults with severe alopecia areata over 24 weeks, with an acceptable safety profile as most adverse effects were transient.

This study found that ritlecitinib was well tolerated in children aged 6 to under 12 years with severe alopecia areata, with ongoing trials examining its efficacy and safety over a 24-week period and in long-term use up to 36 months.

This study found that men receiving enzalutamide and other androgen-deprivation therapies may be at increased risk for QT prolongation and torsades de pointes.

This study reported cold thermal injuries on the scalp in four patients using cold caps to prevent chemotherapy-induced alopecia, suggesting improper application can lead to adverse events.

This study reported that dupilumab, a human monoclonal antibody, induced hair regrowth in patients with alopecia totalis, suggesting its potential as a treatment for this condition.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

In this study, combining baricitinib and prednisone effectively achieved complete hair regrowth in seven out of eight women with very severe alopecia areata, contrasting with less effective results from each drug used alone.

In this observational study, researchers examined U.S. and Canadian patients with alopecia areata and found that while comorbid anxiety/depression correlated with increased patient-reported disease severity, other comorbidities like atopic dermatitis and vitiligo showed no statistically significant differences in clinician-reported AA severity or hair involvement.

This study found a significant positive association between higher air quality index values and the incidence of alopecia areata, with a clear dose-response relationship observed among the participants.

This study found that alcohol dependence is associated with altered HPA axis functioning, with AD patients showing higher hair cortisol concentrations and reduced ACTH and cortisol levels, irrespective of childhood maltreatment history.

This source discusses that while oral JAK inhibitors are used for treating lichen planopilaris and frontal fibrosing alopecia, they carry significant risk of adverse events; two cases showed promising results using tofacitinib cream as a safer topical alternative.

This review concluded that JAK inhibitors are effective in achieving meaningful hair regrowth in moderate to severe alopecia areata, although continuous therapy is often needed to maintain the benefits.

This case study documents a 55-year-old male with advanced NSCLC who experienced toe-predominant paronychia and a papulopustular rash following dacomitinib treatment, with the causality tools indicating a "probable" link, yet the therapy continued successfully without dosage alteration.